A Phase 1 interventional study of TAK-079 and Placebo to TAK-079 in Autoimmune Disease, sponsored by Takeda. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-03.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Autoimmune Diseases with a site in United Kingdom — 15 open to participants now, 22 under way, 11 of them phase 3. Autoimmune Diseases · United Kingdom.
Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, this one is the 38th largest by enrollment of the 65 interventional ones that give a count, is one of 3 that started in 2014, is one of 15 in phase 1, and was the 16th registered.
803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.
Browse Autoimmune Diseases studies →15 of the 73 studies in Autoimmune Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Australia and 17 more countries
Ages 18+
Purespring Therapeutics Limited · Sites in United Kingdom, United States
Ages 18+
Imagine Institute · Sites in United Kingdom, Austria, Belgium and 8 more countries
Takeda · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18+
Immunovant Sciences GmbH · Sites in United Kingdom, United States, Argentina and 12 more countries
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 19 · Phase 3 24 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 40 across 542 interventional studies indexed under Autoimmune Diseases.
Median enrollment 94 across the 65 interventional studies, 2,424 across the 8 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 73 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 4 studies filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Autoimmune Diseases with a site in United Kingdom that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06056297Phase 3X4 PharmaceuticalsA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | 2027-09 |
| NCT06193889Phase 3Kyverna TherapeuticsKYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | 2027-09 |
| NCT06843239Zura Bio IncTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the pharmacokinetic and safety and tolerability profile of TAK-079 following a single intravenous (IV) infusion or subcutaneous (SC) administration at escalating dose levels in healthy participants.
The drug being tested in this study is TAK-079. TAK-079 is being tested to find a safe and well-tolerated dose and to assess how TAK-079 is processed by the body. This study will look at pharmacokinetics, side effects, and laboratory results in people who take TAK-079 and is designed as a randomized single dose-rising study.
Therefore, each subsequent cohort will not start until the previous cohort has completed and the results are reviewed. Each participant will receive TAK-079 or placebo once only as an IV infusion or by SC administration. The starting dose for IV will be 0.0003 mg/kg and SC dose of 0.01 or 0.03 mg/kg was determined based on the no-observed-adverse-effect-level (NOAEL) results from the 13-week good laboratory practice (GLP) monkey toxicology study. If this dose is well-tolerated, the next group will receive a higher dose, etc, until a maximal tolerated dose is reached with the highest dose not to exceed 1.0 mg/kg.
This single-center trial will be conducted in the United Kingdom. The overall time to participate in this study is up to 17 weeks. Participants will make 11 visits to the clinic, including one 10-day period of confinement in the clinic. All participants will be contacted by telephone 14 days after the last visit to the clinic for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-079 0.0003 mg/kg, infusion, intravenously, once.
Drug: TAK-079
TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
Drug: TAK-079
Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
Drug: Placebo to TAK-079
TAK-079 solution
Placebo to TAK-079 solution
Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE was assessed according to severity; mild (transient and easily tolerated by the participant), moderate (causes the participant discomfort and interrupts the participant's usual activities) and severe (causes considerable interference with the participant's usual activities).
Time frame: First dose up to Day 94
Number of Participants Who Meet the Takeda Development Centre (TDC) Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose
Time frame: First dose up to Day 78
Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose
Time frame: First dose up to Day 78
Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose
Time frame: First dose up to Day 78
Cmax: Maximum Observed Serum Concentration for TAK-079
Time frame: Day 1 pre-dose and at multiple time-points (up to Day 78) post-dose
AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079
Time frame: Day 1 pre-dose and at multiple time points (up to Day 78) post-dose
AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-079
Time frame: Day 1 pre-dose and at multiple time-points (up to Day 78) post-dose
Percentage of Participants With Positive Antidrug Antibody (ADA) and Neutralizing Antibody (Nab)
Results for ADA analysis were reported.
Time frame: Baseline up to Day 78
Participants took part in the study at 1 investigative site in the United Kingdom (UK) from 01 August 2014 to 29 April 2016.
| Milestone | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 4 | 4 | 4 | 6 | 6 | 6 | 8 | 6 | 6 | 6 | 6 |
| Completed | 12 | 4 | 4 | 4 | 6 | 6 | 6 | 8 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE was assessed according to severity; mild (transient and easily tolerated by the participant), moderate (causes the participant discomfort and interrupts the participant's usual activities) and severe (causes considerable interference with the participant's usual activities).
| participants | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE: Mild | 6 | 3 | 2 | 1 | 5 | 4 | 2 | 3 | 5 | 4 | 4 | 4 |
| TEAE: Moderate | 5 | 0 | 1 | 2 | 1 | 2 | 4 | 3 | 1 | 2 | 1 | 1 |
| TEAE: Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Meet the Takeda Development Centre (TDC) Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| nanogram per milliliter (ng/mL) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax: Maximum Observed Serum Concentration for TAK-079 | — | — | — | — | — | 21.4 ± 8.3 | 100.4 ± 51.7 | — | — | — | — | 23.0 ± 15.5 |
| nanogram*day per milliliter (ng*day/mL) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079 | — | — | — | — | — | — | — | — | — | — | — | 90.4 ± 83.2 |
| ng*day/mL | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-079 | — | — | — | — | — | — | — | — | — | — | — | 212 ± 103 |
Results for ADA analysis were reported.
| percentage of participants | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Positive Antidrug Antibody (ADA) and Neutralizing Antibody (Nab) | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 33.3 | 16.7 | 0 | 16.7 ± 102.58826 |
| participants | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose | 6 | 2 | 2 | 2 | 1 | 4 | 6 | 4 | 4 | 4 | 3 | 1 |
| participants | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose | 8 | 3 | 3 | 1 | 3 | 5 | 1 | 5 | 4 | 5 | 1 | 0 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 94 days after the last dose of double-blind study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAK-079 Pooled Placebo IV | — | 0/12 (0%) | 11/12 (91.7%) |
| TAK-079 0.0003 mg/kg IV | — | 0/4 (0%) | 3/4 (75%) |
| TAK-079 0.001 mg/kg IV | — | 0/4 (0%) | 3/4 (75%) |
| TAK-079 0.003 mg/kg IV | — | 0/4 (0%) | 3/4 (75%) |
| TAK-079 0.01 mg/kg IV | — | 0/6 (0%) | 6/6 (100%) |
| TAK-079 0.03 mg/kg IV | — | 0/6 (0%) | 6/6 (100%) |
| TAK-079 0.06 mg/kg IV | — | 0/6 (0%) | 6/6 (100%) |
| TAK-079 Pooled Placebo SC | — | 0/8 (0%) | 6/8 (75%) |
| TAK-079 0.03 mg/kg SC | — | 0/6 (0%) | 6/6 (100%) |
| TAK-079 0.1 mg/kg SC | — | 0/6 (0%) | 6/6 (100%) |
| TAK-079 0.3 mg/kg SC | — | 0/6 (0%) | 5/6 (83.3%) |
| TAK-079 0.6 mg/kg SC | — | 0/6 (0%) | 5/6 (83.3%) |
| Event | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/12 | 0/4 | 0/4 | 1/4 | 2/6 | 3/6 | 5/6 | 2/8 | 2/6 | 1/6 | 1/6 | 3/6 |
| Dizziness posturalNervous system disorders | 0/12 | 0/4 | 0/4 | 0/4 | 0/6 | 1/6 | 5/6 | 1/8 | 0/6 | 1/6 | 0/6 | 1/6 |
| Injection site erythemaGeneral disorders | 0/12 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/6 | 1/8 | 5/6 | 0/6 | 1/6 | 1/6 |
| PyrexiaGeneral disorders | 0/12 | 0/4 | 0/4 | 0/4 | 1/6 | 1/6 | 3/6 | 0/8 | 0/6 | 0/6 | 1/6 | 0/6 |
| NasopharyngitisInfections and infestations | 2/12 | 0/4 | 1/4 | 0/4 | 0/6 | 0/6 | 2/6 | 1/8 | 2/6 | 3/6 | 1/6 | 3/6 |
| Injection site painGeneral disorders | 0/12 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/6 | 0/8 | 3/6 | 3/6 | 0/6 | 0/6 |
| ChillsGeneral disorders | 0/12 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 2/6 | 0/8 | 0/6 | 0/6 | 0/6 | 1/6 |
| Feeling hotGeneral disorders | 0/12 | 0/4 | 0/4 | 0/4 | 0/6 | 1/6 | 0/6 | 0/8 | 0/6 | 1/6 | 1/6 | 2/6 |
| SomnolenceNervous system disorders | 0/12 | 0/4 | 0/4 | 0/4 | 0/6 | 1/6 | 2/6 | 0/8 | 0/6 | 1/6 | 0/6 | 0/6 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/12 | 1/4 | 0/4 | 0/4 | 0/6 | 1/6 | 1/6 | 1/8 | 0/6 | 2/6 | 0/6 | 1/6 |
The safety analysis set included all participants who were enrolled, received 1 dose of study drug (after study drug dosing started) including those who did not complete all scheduled study visits.
| Age, Continuous(years) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 35.5 ± 10.61 | 23.5 ± 3.42 | 42.3 ± 12.12 | 32.8 ± 10.72 | 36.2 ± 9.52 | 32.3 ± 5.92 | 35.7 ± 11.60 | 34.9 ± 13.61 | 36.7 ± 10.33 | 31.0 ± 8.15 | 40.8 ± 7.83 | 27.7 ± 8.16 | 34.3 ± 10.19 |
| Sex: Female, Male(Participants) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Male | 12 | 4 | 4 | 4 | 6 | 6 | 6 | 7 | 6 | 6 | 6 | 6 | 73 |
| Race/Ethnicity, Customized(participants) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 8 | 3 | 2 | 3 | 4 | 5 | 5 | 6 | 4 | 3 | 6 | 2 | 51 |
| Black or African American | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 |
| Asian | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 3 | 0 | 3 | 13 |
| Multiracial | 1 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6 |
| Region of Enrollment(participants) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | 12 | 4 | 4 | 4 | 6 | 6 | 6 | 8 | 6 | 6 | 6 | 6 | 74 |
| Smoking Classification(participants) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currently smoking | 4 | 0 | 1 | 0 | 1 | 3 | 0 | 0 | 1 | 1 | 1 | 1 | 13 |
| Never smoked | 6 | 2 | 2 | 3 | 3 | 2 | 4 | 7 | 3 | 4 | 4 | 4 | 44 |
| Ex-smoker | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 17 |
| Caffeine Classification(participants) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Had caffeine consumption | 9 | 3 | 3 | 1 | 6 | 6 | 3 | 3 | 3 | 6 | 5 | 2 | 50 |
| Had no caffeine consumption | 3 | 1 | 1 | 3 | 0 | 0 | 3 | 5 | 3 | 0 | 1 | 4 | 24 |
| Alcohol Classification(participants) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drinks everyday | 5 | 1 | 2 | 1 | 3 | 1 | 4 | 2 | 4 | 1 | 2 | 4 | 30 |
| Never drank | 7 | 3 | 2 | 3 | 3 | 5 | 2 | 6 | 2 | 5 | 4 | 2 | 44 |
| Height(centimeter (cm)) | TAK-079 Pooled Placebo IV | TAK-079 0.0003 mg/kg IV | TAK-079 0.001 mg/kg IV | TAK-079 0.003 mg/kg IV | TAK-079 0.01 mg/kg IV | TAK-079 0.03 mg/kg IV | TAK-079 0.06 mg/kg IV | TAK-079 Pooled Placebo SC | TAK-079 0.03 mg/kg SC | TAK-079 0.1 mg/kg SC | TAK-079 0.3 mg/kg SC | TAK-079 0.6 mg/kg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 174.7 ± 9.17 | 181.3 ± 6.90 | 175.0 ± 8.04 | 179.5 ± 10.91 | 173.8 ± 1.47 | 175.5 ± 7.97 | 173.8 ± 7.03 | 177.8 ± 7.91 | 176.8 ± 3.31 | 181.2 ± 8.80 | 177.8 ± 6.68 | 172.3 ± 4.32 | 176.3 ± 7.32 |
2 further baseline measures are reported on the registry.
The record gives a start of Aug 2014, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mezagitamab